skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration


We have compiled a comprehensive review of all the presentations from the conference, with the key points and our expert insight, for you to download, for free. A full list of events and catalysts that were announced or updated during the conference is included in this report.


Key highlights include:

• The meeting kicked off with the blockbuster announcement that Takeda will acquire Ariad (ARIA) and its oncology portfolio for approximately $5.2b. In March 2016, Takeda announced its strategic roadmap where it placed the oncology, gastroenterology, and central nervous system (CNS) franchises as its top R&D priority moving forward.

• Merck (MRK) released a surprising disclosure that it had filed an sBLA for Keytruda in combination with chemotherapy for first-line NSCLC. The filing was surprising in its reliance on the Phase I/II KEYNOTE-021 study rather than the larger Phase III ‘189 study already ongoing. 

• Surprisingly, the new CEO of Biogen (BIIB) spent little time discussing any potential differentiators for aducanumab in Alzheimer’s disease following the high-profile failure of LLY’s solanezumab.

• Intra-Cellular Therapies (ITCI) provided an update on its expected meeting with FDA regarding Lumateperone (ITI-007) for the treatment of schizophrenia, but was surprisingly quiet on the Phase III development of ITI-007 for the treatment of agitation in patients with dementia including Alzheimer’s disease.

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: